RBM20 is expressed preferentially in cardiac tissue and implicated in cardiomyopathies, while RBM20 antagonists represent a potential therapeutic target in HF management (Bull et al. 2016; Li et al. 2010; Methawasin et al. 2014, 2016; Zhu et al. 2015). Here, RBM20 is linked to hydrops fetalis.